Integra LifeSciences (NASDAQ:IART) Hits New 52-Week Low Following Analyst Downgrade

Shares of Integra LifeSciences Holdings Corporation (NASDAQ:IART) hit a new 52-week low during trading on Friday after Citigroup lowered their price target on the stock from $12.00 to $11.00. Citigroup currently has a sell rating on the stock. Integra LifeSciences traded as low as $11.05 and last traded at $11.81, with a volume of 4785319 shares trading hands. The stock had previously closed at $15.43.

Several other research firms also recently issued reports on IART. JPMorgan Chase & Co. lifted their price target on shares of Integra LifeSciences from $12.00 to $13.00 and gave the stock an “underweight” rating in a research note on Friday. Truist Financial set a $15.00 price target on shares of Integra LifeSciences and gave the stock a “hold” rating in a research note on Wednesday, October 15th. Finally, Weiss Ratings reaffirmed a “sell (d)” rating on shares of Integra LifeSciences in a research note on Wednesday, October 8th. Two research analysts have rated the stock with a Buy rating, two have issued a Hold rating and four have issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Reduce” and a consensus target price of $16.17.

Institutional Investors Weigh In On Integra LifeSciences

Hedge funds and other institutional investors have recently modified their holdings of the stock. Principal Financial Group Inc. boosted its holdings in shares of Integra LifeSciences by 2.5% in the 1st quarter. Principal Financial Group Inc. now owns 433,924 shares of the life sciences company’s stock valued at $9,542,000 after buying an additional 10,492 shares during the period. Wealth Enhancement Advisory Services LLC acquired a new position in shares of Integra LifeSciences in the 1st quarter valued at about $251,000. Victory Capital Management Inc. boosted its holdings in shares of Integra LifeSciences by 1,067.6% in the 1st quarter. Victory Capital Management Inc. now owns 147,982 shares of the life sciences company’s stock valued at $3,254,000 after buying an additional 135,308 shares during the period. Strs Ohio acquired a new position in shares of Integra LifeSciences in the 1st quarter valued at about $400,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in shares of Integra LifeSciences by 16.3% in the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 16,811 shares of the life sciences company’s stock valued at $370,000 after buying an additional 2,357 shares during the period. Institutional investors own 84.78% of the company’s stock.

Integra LifeSciences Price Performance

The company has a debt-to-equity ratio of 1.18, a quick ratio of 0.73 and a current ratio of 1.23. The company’s fifty day moving average price is $14.70 and its 200 day moving average price is $13.81. The firm has a market capitalization of $935.71 million, a price-to-earnings ratio of -1.84 and a beta of 1.21.

Integra LifeSciences (NASDAQ:IART) last posted its earnings results on Thursday, October 30th. The life sciences company reported $0.54 EPS for the quarter, topping the consensus estimate of $0.43 by $0.11. Integra LifeSciences had a negative net margin of 30.87% and a positive return on equity of 12.15%. The firm had revenue of $402.06 million during the quarter, compared to analysts’ expectations of $414.31 million. During the same quarter in the prior year, the firm earned $0.41 EPS. Integra LifeSciences’s quarterly revenue was up 5.6% on a year-over-year basis. Integra LifeSciences has set its Q4 2025 guidance at 0.790-0.840 EPS. FY 2025 guidance at 2.190-2.240 EPS. Equities research analysts expect that Integra LifeSciences Holdings Corporation will post 2.45 earnings per share for the current year.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.